Atlas Venture, established in 1980, is a Cambridge, Massachusetts-based venture capital firm with a global presence. It manages over $2 billion in committed capital across multiple funds. The firm specializes in early-stage investing, focusing on life sciences and technology sectors. Atlas Venture creates and invests in biotech startups led by promising entrepreneurs, aiming to build scalable businesses and realize value. It typically invests $500,000 to $5 million in seed and early-stage rounds, with follow-on financing potentially reaching $10 to $20 million per company. Since 1995, Atlas Venture has been involved with over 350 companies, with 50 acquisitions and 40 IPOs.
400 Technology Square, 10th Floor Cambridge, MA 02139 USA
Laura Alessio
Director of Portfolio operations
Peter Barrett
Partner, Legacy Funds
Bruce Booth
Partner
Ommer Chohan
CFO
Rajesh Devraj
Venture Partner
Maurizio Fazio
Principal
Jernej Godec Ph.D
Principal
David Grayzel
Partner
Julia Pian
Associate
Aimee Raleigh
Principal
Jason Rhodes
Partner
Steven Robinette
Venture Partner
Past deals in Maine
Phylogix
Series B in 2004
Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.